400-0066-400

Participation in CVAIF2024

Home > News > Company News > Participation in CVAIF2024
Participation in CVAIF2024
Update time:2023-10-07 16:17:04 by JONLNBIO
share

Jonln Bio Key Details
Event: 2024 China Vaccine and Antibody Drug Innovation Forum
Date: March 28-29, 2024
Location: Beijing, China
Booth Number: NO.37
 
Recently, we were honored to participate in China Vaccine and Antibody Drug Innovation Forum, a two-day conference where experts, scholars, industry leaders, and representatives of related enterprises gathered to discuss the latest research progress, technological innovation, and market development trends of vaccine and antibody drugs.



Several experts shared new technologies in vaccine development, such as mRNA vaccines and recombinant vaccines. Driven by COVID-19, these technologies have gained rapid development and demonstrated good application prospects.
 
The meeting mentioned the continuous innovation of antibody drugs, especially in the application of targeted therapy and personalized medicine. Experts pointed out that with the advancement of the Human Genome Project, the R&D of antibody drugs will become more precise.
 
Participants discussed how to strengthen the cooperation between vaccines and antibody drugs globally, especially the synergistic development in R&D, production, and marketing. It was agreed that international cooperation would be an important path to break down technical barriers and enhance the competitiveness of the industry in the future.
 
After attending this forum, we deeply realize the importance of vaccine and antibody drug innovation and the huge market potential. In the future, we will continue to devote ourselves to R&D and innovation, strengthen cooperation with domestic and foreign enterprises, and promote the marketization of our products.
 
Finally, this forum has provided us with a good communication platform, which not only broadens our horizons, but also provides new opportunities for collaborative innovation in the industry. We look forward to meeting with experts, scholars, and colleagues again to explore the future development of vaccines and antibody drugs.


 

Top